Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 317-323

  Bao, Huizheng ^a,b   Yu, Dehai ^a   Wang, Jun ^a   Qiu, Tian ^a   Yang, Jianli ^a   Wang, Li ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b JILIN PROVINCIAL CANCER HOSPITAL   (China)

Author keywords

Anthracycline; Anti p53 antibodies; Breast cancer; Clinical tumor response; Neoadjuvant chemotherapy; Taxane

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBODY; BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; PROTEIN P53 ANTIBODY; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; PROTEIN P53; TAXOID; TUMOR MARKER;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45549095305     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f3d018     Document Type: Article

References (18)

1. Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 12:159-164.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
3. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biology 1981; 91:479-487.
4. Smith PJ, Soue's S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br J Cancer 1994; 23 (Suppl):S47-S51.
5. Sikov WM. Locally advanced breast cancer. Curr Treat Options Oncol 2000; 1:228-238.
6. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant paclitaxel plus pirubicin combination. BMC Cancer 2007; 7:36.
7. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics. Nat Clin Pract Oncol 2005; 2:598-599.
8. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altorjai G, et al. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 2006; 6:81.
9. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004; 9 (Suppl 2):24-32.
10. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocrine-Related Cancer 2002; 9:183-195.
11. Tiezzi DG, De Andrade JM, Candido dos Reis FJ, Marana HR, Ribeiro-Silva A, Tiezzi MG, et al. Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Pathology 2006; 38:21-27.
12. Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical biological parameters. Breast Cancer Res Treat 2005; 93:111-115.
13. Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9:5582-5588.
14. Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, et al. Chemotherapy response of breast cancer depends on Her-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7:1577-1581.
15. Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, et al. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med 2005; 23:189-194.
16. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003; 97:1758-1765.
17. Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, et al. Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci 2007; 104:232-242.
18. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007; 9:R34.